Objectives. To investigate the effects of soluble interleukin-1 (IL-1) type II receptor (sIL-1RII ) on a number of clinical, biochemical and histological parameters in rabbit antigeninduced arthritis.
Interleukin-1b (IL-1b) is one of the key mediators
We have used rat soluble IL-1RII (sIL-1RII ) to involved in a number of chronic inflammatory and investigate its effects in rabbit antigen-induced arthritis. autoimmune diseases. IL-1b binds to cell surfaces via In this rabbit model, a chronic monoarticular inflamtwo distinct receptors [1]: type I ( IL-1RI ), an 80 kDa matory arthritis develops, which closely resembles the protein expressed mainly on T cells, endothelial cells joint pathophysiology of rheumatoid arthritis (RA), and fibroblasts, containing a transmembrane signalling especially with regard to the synovial histopathology domain [2] ; type II (IL-1RII ), a 60-68 kDa protein and biochemistry and its response to anti-arthritic drugs expressed mainly on B cells, neutrophils and monocytes [8] [9] [10] [11] . In this model, a number of cytokines such as with no known signal transduction capabilities [3] [4] [5] .
IL-1b and tumour necrosis factor alpha ( TNF-a) are These two cellular receptors also have markedly differing likely to be involved in the disease pathogenesis, but the affinities for the family of IL-1 agonist molecules: IL-1a, present data are the first evidence that biological inhib-IL-1b and IL-1ra [6 ] . IL-1RI has the highest affinity for ition of IL-1b can markedly reduce arthritis in this IL-1ra & IL-1a $ IL-1b, while in the case of IL-1RII, animal model. the order of affinities is IL-1b & IL-1a > IL-1ra [7] . The preferential binding of IL-1b to the 'decoy' nonsignalling IL-1RII, rather than the signalling IL-1RI, Materials and methods may therefore be a mechanism by which the soluble form of the type II receptor can act as a specific Female dwarf Russian rabbits weighing between 2.5 and antagonist.
2.8 kg were used throughout the study, which was performed in accordance with the animal experimentation guidelines and laws laid down by the Swiss Federal was prepared, purified and tested for biological activity buffered saline. Total cell numbers were counted on a as described previously (paper submitted ).
Z1 Coulter Counter, the samples centrifuged and the Rabbits were sensitized intradermally at two sites to cell-free synovial fluid aliquoted and frozen at −20°C methylated bovine serum albumin (mBSA) homogenized prior to assay. The knees were then processed for 1:1 with complete Freund's adjuvant on days -28 and undecalcified histology using a Histodur plastic embed--14 (0.5 ml containing 4 mg/ml mBSA). On day -7, a ding method (Leica AG, Germany). Sections (5 mm) skin test was performed to assess the immune status of from both the control and arthritic knees were cut the animal by examining the delayed-type hypersensitivon a Polycut S heavy-duty sledge microtome (Leica ity (DTH ) reaction to the soluble antigen on days -6 AG, Germany). After staining adjacent sections with and -5. The results of this test were used to assign the toluidine blue (metachromatic stain for cartilage animals to the three matched treatment groups. On day proteoglycans) and haemotoxylin and eosin (general 0, a blood sample was taken from each animal and the morphology stain), the slides were number coded as left initial right and left joint diameters measured. The knee/right knee pairs from each animal. The slides were rabbits were then sedated with 1 mg/kg s.c. acepromazread in a blinded fashion (JD). The left knee joint from ine before anaesthesia with an ultra-short-acting barbiteach animal was examined for comparison, immediately urate (methohexital sodium, 10 mg/kg i.v.) for the intraprior to scoring the arthritic right knee joint from the articular injections and s.c. implantation of the minisame animal, to establish the anatomy of the nonpumps (Alzet Corp.). The right knee received 0.5 ml of arthritic knee in each case. A subjective scoring system 2 mg/ml mBSA in 5% glucose solution (antigen-injected was used to assess inflammatory cell infiltrate/hyperknee), while the left knee received 0.5 ml of 5% glucose plasia, cartilage proteoglycan loss and erosive damage solution alone (vehicle-injected knee). Mini-pumps were to bone and cartilage, where 1 is the minimum score aseptically implanted between the shoulder blades into and 5 is the maximum score for each parameter coma s.c. pouch produced by blunt dissection. At the same pared to the control sections ( left knee) in each case. A time, the rabbits received a bolus i.v. injection of either detailed explanation of the scoring system used for each vehicle (500 ml ), low-dose sIL-1RII (13.4 mg) or highof the individual histological parameters is given in dose sIL-1RII (40.2 mg) to cover the initial period until Table 1 . The tissue swelling, observed between the outer the mini-pumps started accurate s.c. drug delivery. The ends of both menisci and the joint capsule, was measured knee joint diameters were again measured on days 1, 2, on the joint sections using a ruled graticule and expressed 7, 9 and 14 after the intra-articular injection and further in millimetres. blood samples taken at the same time points, except on Rabbit IL-1a and IL-1b were measured in the synovial day 1. Blood samples were centrifuged, the cell-free fluid samples using commercially available RIA kits plasma aliquoted and stored at −20°C prior to from Endogen, following the manufacturer's instrucassay.
tions. Concentrations of PGE 2 , in both plasma and On day 14, the rabbits were killed by an overdose of synovial fluid samples, were determined using a Biotrak thiopentane barbiturate, and a sample of synovial fluid was lavaged from each knee with 1 ml of heparinized EIA kit from Amersham. aThe degree of loss of articular cartilage metachromasia staining can easily be determined by comparison to the metachromasia observed in the growth plate cartilages.
Results
Injection of mBSA in 5% glucose intra-articularly resulted in an arthritis which was observed clinically as a measurable increase in joint diameter and reluctance to put weight on the antigen-injected leg. This limping is most likely to result from pain in the injected knee, but the pain could not be clinically investigated further, in an objective way, during this experiment.
The effects of sIL-1RII on the degree and time course of joint swelling are shown in Fig. 1 . In the control animals, the rapid increase in joint diameter was maximal on day 2, declining gradually thereafter to day 14. In sIL-1RII-treated animals, there was dose-related inhibition of knee swelling which followed the swelling pattern in the control animals, albeit at a reduced level. inhibition of soft-tissue swelling at both low and high doses of sIL-1RII. A significant effect was also seen on the reduction of joint erosions at the high dose, while no effects were observed on inflammatory cell infiltration or proteoglycan loss.
The effects of sIL-1RII on synovial fluid concentrations of IL-1a are shown in Fig. 3 . In the control and low-dose sIL-1RII animals, the concentration of IL-1a was higher in the synovial fluid from the arthritic knee compared to the control knee. In contrast, the synovial fluid concentrations in the high-dose group were not significantly different in the control and arthritic knees, but the high-dose right knee IL-1a concentration was significantly reduced compared to the control right knee. Figure 4 illustrates the effect of sIL-1RII on synovial fluid concentrations of IL-1b. In the control and low-F. 3. The effect of sIL-1RII on synovial fluid IL-1a concentrations in the rabbit antigen-induced arthritis model. Treatment was administered as an i.v. bolus ( loading dose), followed by s.c. infusion via minipump. Each point represents the mean ± ... of n = 5 animals. *P < 0.05 significant vs saline-treated group, one-way ANOVA followed by Dunnett's test for multiple comparisons post hoc. NS, not significant. dose sIL-1RII animals, the concentration of IL-1b was again higher in the synovial fluid from the arthritic knee compared to the control knee; however, the difference was much more marked in the saline-treated group. Similar to the results for IL-1a, the synovial fluid concentrations of IL-1b in the high-dose group were not significantly different in the control and arthritic knees. In contrast to the IL-1a results, the right knee concentra- The effects of sIL-1RII on synovial fluid counts are animals. *P < 0.05 and **P < 0.01 significant vs saline-treated shown in Table 2 . There was a marked increase in the group, one-way ANOVA followed by Dunnett's test for multiple comparisons post hoc. NS, not significant. number of cells in the arthritic right knee joints and right knee synovial fluid PGE 2 concentrations. There was no significant difference in the mean PGE 2 concentrations determined in the synovial fluid from sIL-1RII-treated animals compared to saline-treated animals. In contrast, there was a marked and doserelated reduction in plasma PGE 2 concentrations, with the concentrations in the high-dose group reduced to below the detection limit of the assay. The concentrations of PGE 2 in the left knees of all groups were also below the detection limit of the assay (data not shown).
Discussion
This study clearly demonstrates that infusion of sIL-1RII is effective in a rabbit model of RA. The dose- same antigen. Our model is a modification of the system originally described by Dumonde and Glynne [8] , and it reflects most accurately the chronicity of the disease [9] , the pathological changes in synovium and the
Treatment group
Left knee Right knee pattern of tissue damage observed in rheumatoid joints [10] . Antigen-induced arthritis, especially in the rabbit, formed [16, 17] as well as a number of clinical trials in RA to evaluate these agents [18, 19] . In the mouse compared to the controls. However, no significant antigen-induced arthritis model, re-injection of a small difference was seen between the left or right knees of amount of mBSA can elicit a flare-up of arthritis either sIL-1RII-treated group compared to the salinewith expression of IL-1 in the inflamed synovium. treated left or right knees. Previous experiments have Administration of anti-IL-1a and b antibodies can demonstrated that 85-90% of the leucocytes present in inhibit joint swelling and pathology in both the flare-up synovial fluid of the inflamed knee at day 14 are
[20] and standard mouse antigen-induced arthritis model polymorphonuclear cells and 10-15% mononuclear cells, [21] . The effect of recombinant human IL-1ra has also and that this ratio does not alter significantly with any been investigated in this mouse model and shown to therapy tested so far (J. Dawson, unpublished findings). reduce cartilage damage [22] . In contrast, neutralizing Table 3 illustrates the effects of sIL-1RII on plasma anti-TNF-a antibody was ineffective on this parameter. These results indicate that in this model, IL-1 but not T 3. Concentrations of PGE 2 (pg/ml ) in synovial fluid from right TNF is responsible for cartilage damage.
knee joints (arthritic) and plasma in rabbit antigen-induced arthritis.
In a rabbit antigen-induced arthritis study using an arthritis, significantly reduced knee swelling, but had no (500 ml + 5 ml/h) effect on leucocyte influx, nor on proteoglycan loss from Low-dose sIL-1RII 1066 ± 338NS 54 ± 16* cartilage. In contrast, our present rabbit study with inhibitory effects not only on swelling, but also histologically on joint damage/erosions. In addition, a recent *P < 0.05 and **P < 0.01 ANOVA+post hoc Dunnett's test for study in rat antigen-induced arthritis using the same multiple comparisons. NS, not significantly different from the saline control group. <dl, below the detection limit of the assay (2.5 pg/ml ).
soluble IL-1RII (paper submitted ) demonstrated significant dose-related inhibition of knee swelling, as antly demonstrated in vitro [30] , strengthening the above hypothesis further. well as inhibition of both inflammatory cell influx and joint damage on histological examination after adminisIn our current study, the concentrations of IL-1a and, to a greater extent, IL-1b in synovial fluid were also tration of a dose of 2 mg/h/animal. Recently, an alternative approach to cytokine inhibition has been described significantly reduced in a dose-related manner. The observed reduction of IL-1a vs IL-1b in synovial fluid in rabbit antigen-induced arthritis using adenovirus gene transfer of IL-1 and TNF-a soluble type I receptors is consistent with the relative binding affinities of each of these molecules for IL-1RII, and additionally suggests locally into knee joints [23] . These workers found that, individually, sIL-1 receptor reduced cell influx and cartilthat the soluble receptor molecule enters the inflamed joint after systemic administration. Indeed, it has been age degradation, while sTNF-a receptor was only moderately effective on cell influx. The best effects were seen reported that soluble IL-1 receptors can reduce the concentrations of IL-1b and IL-1ra which can be when both agents were transfected together, and some beneficial effects were additionally seen in the contradetected in synovial fluid by ELISA [31] . Our study indicates that the same is true when RIAs are used to lateral arthritic knee which was not treated directly. These results, taken together, seem to confirm in this detect cytokine concentrations in rabbit synovial fluid. Treatment with sIL-1RII had no effect on the concenmodel that IL-1 is the major cytokine responsible for the hard-tissue destruction, while TNF-a has little or tration of PGE 2 which could be detected in synovial fluids, but did give a significant, dose-related reduction no direct effect on this aspect of the arthritis pathology. These results also agree with previously reported findings in the concentration of PGE 2 which could be measured in plasma from the same animals. PGE 2 production can using exogenous administration of cytokines [24-27]. However, there seems to be a growing consensus that be induced from both synoviocytes [32] and articular chondrocytes [33] in vitro by IL-1b, suggesting that inhibition of both of these cytokines is likely to be required to show real benefit in RA.
either or both of these sites are probably responsible for the production of PGE 2 detected in rabbit synovial fluid. In human clinical trials, the major therapeutic efforts have so far evaluated the effects of systemic or local
Whether the plasma concentrations of PGE 2 represent an excessive local production in the joints, which then application of soluble IL-1ra and sIL-1RI (to investigate IL-1 inhibition) and anti-TNF-a antibody and soluble leaks into the circulation, or a separate systemic induction of PGE 2 , is open to question, and would require TNF-a receptor fusion proteins (to examine the effects of TNF-a inhibition) [18] . The results obtained so far further investigation. However, since synovial fluid PGE 2 production was not affected by sIL-1RII, this with the anti-TNF-a therapies seem to have shown good efficacy [28] ; however, whether these therapies can demstrongly suggests that mediators other than IL-1 may be major inducers of PGE 2 synthesis in inflamed joints. onstrate longer term relief with acceptable side-effect profiles remains to be seen. The results obtained with
In conclusion, sIL-1RII has been used to test the concept that this rabbit model of RA arthritis is IL-1 the anti-IL-1-directed therapies, while showing early promise in open trials, have been somewhat less efficadependent, and the results obtained indicate that this is indeed the case. Results from similar experiments using cious in subsequent randomized placebo-controlled ones [28] . The binding properties of IL-1a and IL-1b vs anti-TNF-a antibodies and gene therapy serve to validate this model as the best system for testing therapies IL-1ra to the two IL-1 receptors may provide explanations for this. Firstly, a very large excess of IL-1ra will which are ultimately destined for the treatment of RA. be required in vivo to compete out the binding of IL-1b to the type I receptor and prevent cell activation since only a very low receptor occupancy (<1%) is required
